Details
| Stereochemistry | UNKNOWN |
| Molecular Formula | C12H18ClN |
| Molecular Weight | 211.731 |
| Optical Activity | ( - ) |
| Defined Stereocenters | 0 / 1 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
CC(CC1=CC=CC=C1)NCCCCl
InChI
InChIKey=XXVROGAVTTXONC-UHFFFAOYSA-N
InChI=1S/C12H18ClN/c1-11(14-9-5-8-13)10-12-6-3-2-4-7-12/h2-4,6-7,11,14H,5,8-10H2,1H3
DescriptionCurator's Comment: description was created based on several sources, including, http://ec.europa.eu/health/documents/community-register/2000/200003093430/anx_3430_en.pdf
Curator's Comment: description was created based on several sources, including, http://ec.europa.eu/health/documents/community-register/2000/200003093430/anx_3430_en.pdf
Mefenorex or (+/-)N-(3-chloropropyl)-1-methyl-2-phenylethylamine is an N-alkylated analogue of amphetamine. The therapeutic efficacy of mefenorex as an adjunctive support in the treatment of obesity for limited periods of time, as well as its ability to be well tolerated, has been amply demonstrated. Mefenorex is considered to be racemic mixture, no available data regarding enantiospecific pharmacological activity of the compound.
CNS Activity
Approval Year
PubMed
| Title | Date | PubMed |
|---|---|---|
| Toxicokinetics of amphetamines: metabolism and toxicokinetic data of designer drugs, amphetamine, methamphetamine, and their N-alkyl derivatives. | 2002 Apr |
|
| Precursor medications as a source of methamphetamine and/or amphetamine positive drug testing results. | 2002 May |
Patents
| Name | Type | Language | ||
|---|---|---|---|---|
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
7FT4O2NC8G
Created by
admin on Sat Dec 16 10:30:28 UTC 2023 , Edited by admin on Sat Dec 16 10:30:28 UTC 2023
|
PRIMARY | |||
|
111051-42-4
Created by
admin on Sat Dec 16 10:30:28 UTC 2023 , Edited by admin on Sat Dec 16 10:30:28 UTC 2023
|
PRIMARY |
SUBSTANCE RECORD
